Jeffrey A. Shaman, PhD, MS, is the Chief Science Officer at Coriell Life Sciences (CLS), an international leader in precision medicine. Leveraging extensive experience in genetics and pharmacology, he is a leading expert in the rapidly evolving field of pharmacogenomics (PGx), the study of how an individual’s DNA impacts his or her response to medication. Most importantly, Dr. Shaman plays a critical role in bridging the gap between genetic science and clinical application. This includes translating decades of cutting-edge genetic research into actionable insights on the safest and most effective medications for individuals based on their unique DNA and dozens of other factors.
Driven to advance public health, Dr. Shaman is focused on enabling the delivery of personalized medicine at scale and empowering the most precise medical care worldwide. He consults with large employers, public and private payer organizations, healthcare systems, academic institutions, and laboratories around the globe, advising them on how to eliminate trial-and-error prescribing, improve population health, and control rising healthcare costs.
Dr. Shaman is dedicated to setting the industry standard for PGx and pioneering new advancements in the field. Along with his team, he actively researches and presents findings in top peer-reviewed journals and at leading industry events. He is an active member of the Clinical Pharmacogenetics Implementation Consortium (CPIC), Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community, Personalized Medicine Coalition (PMC), Pharmacogenomics Global Research Network (PGRN), and other organizations.
Dr. Shaman holds a doctoral degree from The Johns Hopkins University School of Medicine in Pharmacology and Molecular Sciences, where his research centered on DNA, epigenetics, and nuclear structure and function. He earned his Master of Science degree from The University of Medicine and Dentistry of New Jersey in Cell & Developmental Biology. Dr. Shaman held a faculty position at the University of Hawai‘i Institute of Biogenesis Research before serving a fellowship at Harvard Medical School and implementing a translational research program at Beth Israel Deaconess Medical Center and the Bedford Stem Cell Research Foundation.
Editorial – Pharmacogenomics: From Bench to Bedside and Back Again (Frontiers in Genomics)
Idiopathic Symptoms Resolved by Pharmacogenomics-Enriched Comprehensive Medication Management: A Case Report (Cureus)
Real-World Impact of a Pharmacogenomics-Enriched Comprehensive Medication Management Program (Journal of Personalized Medicine/MDPI)
Consequences of CYP2D6 Copy-Number Variation for Pharmacogenomics in Psychiatry (Frontiers in Psychiatry)
Diagnosing Bacterial Vaginosis with a Novel, Clinically-Actionable Molecular Diagnostic Tool (Journal of Applied Microbiological Research)
Molecular Diagnosis of Vaginitis: Comparing Quantitative PCR and Microbiome Profiling Approaches to Current Microscopy Scoring (Journal of Clinical Microbiology®)